Compare NSYS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSYS | HOWL |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 30.7M |
| IPO Year | 1996 | 2021 |
| Metric | NSYS | HOWL |
|---|---|---|
| Price | $12.25 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 15.7K | ★ 504.6K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.85 | 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.01 | N/A |
| 52 Week Low | $6.50 | $0.49 |
| 52 Week High | $15.39 | $2.23 |
| Indicator | NSYS | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 25.23 |
| Support Level | $8.62 | N/A |
| Resistance Level | $15.11 | $0.75 |
| Average True Range (ATR) | 0.96 | 0.07 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 28.26 | 0.06 |
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.